Asia Pacific Biotechnology And Pharmaceutical Services Outsourcing Market Size | Companies
The Asia Pacific biotechnology and pharmaceutical services outsourcing market size was exhibited at USD 19.18 billion in 2023 and is projected to hit around USD 35.23 billion by 2033, growing at a CAGR of 6.27% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 20.38 Billion |
| Market Size by 2033 | USD 35.23 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 6.27% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | End-use, Service, Country |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | China; India; Japan; Australia; South Korea; Thailand |
| Key Companies Profiled | Dr. Reddy’s Laboratories; MSN Laboratories; Syngene International Ltd.; Aragen Life Sciences Ltd.; Bellen; Arlak Biotech Pvt. Ltd.; Gracure Pharmaceuticals Ltd.; Nvron Life Science |
The market growth can be attributed to the increasing number of contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) in countries, such as China and India.
The Asia Pacific biotechnology and pharmaceutical services outsourcing market held a share of 42.4% of the global biotechnology and pharmaceutical services outsourcing market revenue in 2023. Several biotechnology and pharmaceutical companies from developed economies in North America and Europe are opting to outsource various business functions, such as manufacturing, research & development, distribution, drug development, and clinical trials, to contract organizations operating in the region. In recent decades, countries, such as China, India, and Japan, have experienced advancements in industrial infrastructure, availability of technology, and accessibility to resources.
This has resulted in the establishment of outsourcing industry participants who have been running businesses successfully with continuous enhancements. It has also resulted in the availability of experienced professionals, accessibility to innovative technologies, and lower costs of labor and drug development & production. A growing number of contract development and manufacturing organizations (CDMOs) is primarily driving the growth of this market in Asia Pacific. Some of the CDMOs operating in the region are Piramal Pharma Solutions, Syngene International Limited, Sai Life Sciences, and others.
Based on the end-use, the pharmaceutical companies segment held the highest revenue share of 58.11% in 2023. China has been one of the most preferred locations for many pharmaceutical businesses, in terms of outsourcing research and manufacturing functions. In recent years, India has also been emerging as an alternative for similar services. Positive changes in industrial infrastructure, supportive government initiatives, increasing availability of skilled professionals, and accessibility to advancing technology have attracted many pharmaceutical companies from the U.S., Europe, and other parts of the world.
The biotech companies segment is expected to experience a CAGR of 6.66% from 2024 to 2033. India has been one of the leading manufacturers of generic drugs and exports large amounts of generics to countries, such as the U.S. and others. In recent years, factors, such as lower costs for manufacturing, clinical trials, distribution, world-class facilities provided by CDMOs in the region, the presence of technical expertise, and skilled professionals have driven the growth of this segment.
The consulting services segment dominated the regional market and held a revenue of 23.19% in 2023. Pharmaceutical industry consulting services include clinical development, regulatory affairs, strategic planning, business development, quality management, and more. In addition, aspects, such as R&D, resource management, digital transformation, Environmental, Social, and Governance (ESG), risks & regulations, sales & marketing, and medical technology are also part of consulting services provided by organizations to leading companies in the biotechnology and pharmaceutical industry.
The training & education segment is expected to witness a CAGR of 4.11% from 2024 to 2033. Outsourcing functions, such as employee skill development, learning, and development has been one of the prominent trends as many pharmaceutical companies have been focusing on their core competencies and strengths. Cost-effective outsourcing services offered by organizations in the market, emerging providers of e-learning solutions, and talented instructors have been fueling the segment's growth.
China Biotechnology And Pharmaceutical Services Outsourcing Market Trends
China biotechnology and pharmaceutical services outsourcing market dominated the regional industry and accounted for a share of 29.3% in 2023. This is primarily due to factors, such as lower labor costs, reputation as one of the most preferred alternatives for outsourcing services, and availability of infrastructure. In addition, favorable government policies that have been welcoming pharmaceutical companies to outsource their business functions such as clinical trials and drug development to contractors in China have been driving the market.
India Biotechnology And Pharmaceutical Services Outsourcing Market Trends
The biotechnology and pharmaceutical services outsourcing market in India is expected to experience a significant CAGR of 6.72% from 2024 to 2033. This can be attributed to advancements in industrial infra, availability of world-class facilities, presence of skilled professionals, and lower costs associated with procurement of materials and other business area
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Asia Pacific biotechnology and pharmaceutical services outsourcing market
End-use
Service
Country
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers